Wednesday - June 11, 2025
DEERFIELD, Ill. / Feb 13, 2025 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Citi - 2025 Medtech & Life Sciences Access Day on Thursday, February 27, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, August 26, 2025.
About Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.
Last Trade: | US$31.72 |
Daily Change: | 0.87 2.82 |
Daily Volume: | 4,589,657 |
Market Cap: | US$16.200B |
May 01, 2025 March 04, 2025 February 25, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load